NCT07020221 2026-04-03
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
Verastem, Inc.
Revolution Medicines, Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
University of Maryland, Baltimore
Peking University Cancer Hospital & Institute